San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Cellebration Life Sciences is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Tim Kopatich played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cellebration Life Sciences
Cellebration Life Sciences, Inc. has teamed with the Global Institute of Stem Cell Therapy and Research (GIOSTAR) to provide world-class research in the development of a curative treatment for Type 2 Diabetes. Headed by Anand Srivastava, PhD, considered by many as the Father of Stem Cell Research, Cellebration currently has underway a U.S. Food and Drug Administration (FDA) Pre-Investigational Clinical Trial application. Results from a preliminary clinical trial conducted in India indicate an up to 75% reduction in insulin usage in clinical trial patients. The U.S. Department of Health and Human Services estimates that more than 41 million Americans have or are pre-disposed to Type 2 Diabetes. This represents a market size for treatments of more than $300 billion annually. Globally, the World Health Organization estimates that close to 500 million people suffer from this disease representing a market size for treatments of more than $800 billion per year. The success of Cellebrations Clinical Trial is expected to significantly alter the worldwide strategy for the treatment of this devastating disease and is anticipated to accrue significant benefits to Cellebrations shareholders.

To learn more about Cellebration Life Sciences, visit http://cellebrationlifesciences.com/

Contact:
Tim Kopatich, Chief Executive Officer
858-337-9678
tim.kopatich@cellebrationlifesciences.com
https://www.linkedin.com/in/timothy-kopatich-887297b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved